Current drug dosing guidelines often rely on population averages, leading to suboptimal dosages for individual patients and increasing the risk of adverse drug reactions or therapeutic failure. Traditional dosing methods do not fully account for inter-patient variability in drug metabolism, genetic factors, and other patient-specific characteristics.

This startup offers a suite of pharmacogenomic and pharmacometric tools designed to personalize drug dosing based on individual patient data. The platform integrates peer-reviewed drug models with patient-specific information to predict optimal dosages, reduce adverse reactions, and mitigate population bias inherent in standard dosing guidelines. By incorporating genetic information and pharmacokinetic/pharmacodynamic modeling, the system enables clinicians to tailor drug therapy to each patient's unique needs. The platform also integrates with electronic health records (EHRs) to streamline the dosing process and minimize errors.

Access to a library of peer-reviewed pharmacometric drug models

Integration of pharmacogenomic data to personalize dosing recommendations

SMART Apps and direct EHR integrations for automated data retrieval and documentation

Input anomaly detection algorithms to minimize the risk of incorrect assessments

Support for payer formularies and clinic-level dosing thresholds

Language localization for international use

The primary target audience includes pharmacists, pharmacologists, and physicians who seek to personalize drug dosing and improve patient outcomes by leveraging pharmacogenomic and pharmacometric data.

The company operates on a pay-per-use model, enabling smaller hospitals and clinics to access advanced dosing algorithms without large upfront investments; discounted pricing is available for under-developed countries and charitable health organizations.